TD Cowen Reiterates Buy Rating on Travere Therapeutics, Inc. (TVTX)

Market Context

Travere Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $62.76 with a market capitalization of $3.1B. The stock has gained 293.2% over the past 52 weeks.

Analyst coverage from TD Cowen provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Travere Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Travere Therapeutics, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 05, 2026	Evercore ISI Group	Outperform	N/A
Aug 05, 2026	Citigroup	Buy	N/A
Aug 05, 2026	TD Cowen	Buy	N/A
Aug 05, 2026	Guggenheim	Buy	N/A
Jul 30, 2026	Canaccord Genuity	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View TVTX Stock Page